Heliotis and Digital Surf announced that MountainsMap Imaging Topography surface metrology software based upon Digital Surf's Mountains Technology will be supplied with Heliotis M3 and M3-XL 3D Optical Profilers.
EVG will integrate Eulitha's PHABLE mask-based ultraviolet (UV) photolithography technology with EVG's automated mask aligner product platform with the goal of developing a low-cost-of-ownership (CoO) nanopatterning solution to enable the production of high-brightness light emitting diodes (HB-LEDs).
Delong America is pleased to announce that we will have the LVEM5 benchtop electron microscope on display at the 10th Asia-Pacific Microscopy Conference (APMC 10), the 2012 International Conference on Nanoscience and Nanotechnology (ICONN 2012) and the 22nd Australian Conference on Microscopy and Microanalysis (ACMM 22).
Nanometrics Incorporated, a leading supplier of advanced process control systems and solutions, today announced a significant milestone marking the adoption of its optical critical dimension (OCD) technology.
FEI, a leading instrumentation company providing imaging and analysis systems for research and industry, today announced that it has acquired ASPEX Corporation of Delmont, PA. ASPEX provides rugged scanning electron microscopes (SEMs) and related services for environmentally demanding military, industrial and factory floor applications.
Tempe, Arizona based SDCmaterials, the global leader in development of advanced high performance catalyst materials, is pleased to announce the commencement of field trials for their novel Nano-Nano-Micron (NNm) emission control catalyst product.
Intertek Cantox, a leading provider of scientific and regulatory consulting services to the food, chemical, and pharmaceutical industries, announces the development of a method to promote high quality nanotoxicology studies allowing companies to ensure the safety of nanotechnology and nanomaterials based products entering the market.
Blend Therapeutics, a biotechnology company discovering and developing a new class of integrative combination medicines, announced the company's founding and strategic mission to develop innovative combination medicines with novel pharmacological profiles designed to target distinct disease pathways with optimal efficacy and safety.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi and obesity, announced today that they have entered into a collaboration and joint licensing agreement.
Arrowhead Research Corporation, a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, Adipotide, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound.